Jul292021 Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease July 29, 2021
Jun32021 Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73 (blarcamesine) for the Treatment of Cardiac Dysfunctions June 3, 2021
May132021 Anavex Life Sciences Reports Fiscal 2021 Second Quarter Financial Results And Business Outlook May 13, 2021
May72021 Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit May 7, 2021
May62021 Anavex Life Sciences to Announce Fiscal 2021 Second Quarter Financial Results and Business Outlook on Thursday, May 13, 2021 May 6, 2021
May52021 Anavex Life Sciences Appoints Former FDA Officer as Senior Vice President for Nonclinical Development May 5, 2021
Apr82021 Anavex Life Sciences to Present at the 20th Annual Needham Virtual Healthcare Conference April 8, 2021
Mar162021 Anavex Life Sciences Reports ANAVEX®2-73 (blarcamesine) featured as a Disease-Modifying Small Molecule in Phase 3 Clinical Trials in a New Publication in Medical Journal titled “Future Avenues for Alzheimer’s Disease Detection and Therapy” March 16, 2021
Feb222021 Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day® February 22, 2021
Feb192021 Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual Summit – West Coast February 19, 2021
Feb82021 Anavex Life Sciences to Announce Fiscal 2021 First Quarter Financial Results and Business Outlook on Thursday, February 11, 2021 February 8, 2021
Jan112021 Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s Disease January 11, 2021
